| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | IGF2R; MPR1; MPRI; CIMPR; M6P-R; MPR300; CI-M6PR; MPR 300; M6P/IGF2R |
| Entrez GeneID | 3482 |
| clone | 4F1G1 |
| WB Predicted band size | 274kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD222 (AA: 160-311) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD222(IGF2R)抗体的模拟参考文献示例(仅供格式参考，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *Targeting CD222 in Cancer Therapy: A Novel Monoclonal Antibody Approach*
**作者**: Smith A, et al.
**摘要**: 研究开发了一种靶向CD222的单克隆抗体，通过体外和体内实验证明其可抑制肿瘤细胞增殖并增强化疗药物敏感性，机制可能与阻断IGF2信号通路相关。
---
2. **文献名称**: *CD222 Antibody-Drug Conjugates for Precision Oncology*
**作者**: Johnson R, et al.
**摘要**: 报道了一种基于抗CD222抗体的药物偶联物(ADC)，在多种实体瘤模型中显著提高药物靶向性，降低系统性毒性，提示其在精准治疗中的潜力。
---
3. **文献名称**: *Structural Characterization of CD222 Antibody Binding Epitopes*
**作者**: Lee H, et al.
**摘要**: 通过X射线晶体学解析了CD222与其特异性抗体的复合物结构，揭示了抗体结合表位的关键氨基酸残基，为优化抗体亲和力提供理论依据。
---
4. **文献名称**: *CD22 as a Biomarker in Neurodegenerative Diseases: Diagnostic Implications*
**作者**: Müller S, et al.
**摘要**: 探讨了抗CD222抗体在阿尔茨海默病模型中的诊断价值，发现其可特异性识别脑脊液中异常表达的CD222片段，提示其作为生物标志物的可能性。
---
**注意**：以上文献为模拟示例，实际研究中请通过PubMed、Google Scholar等平台检索真实文献(关键词：CD222 antibody, IGF2R therapeutic, CD22 cancer等)。
CD222 antibody targets the CD222 antigen, also known as the insulin-like growth factor 2 receptor (IGF2R). CD222 is a transmembrane glycoprotein primarily involved in intracellular trafficking, lysosomal enzyme sorting, and regulation of insulin-like growth factor 2 (IGF2) signaling. It functions as a scavenger receptor by binding and internalizing IGF2. a critical mitogen, thereby modulating cell growth and differentiation. CD222 also participates in the activation of transforming growth factor-beta (TGF-β) through interaction with latent complexes.
CD222 is ubiquitously expressed in various tissues, with roles in embryogenesis, tumor suppression, and metabolic regulation. Dysregulation of CD222 has been linked to cancers, neurodegenerative disorders, and developmental abnormalities. For instance, loss-of-function mutations in CD222 are associated with increased IGF2 bioavailability, promoting tumor growth. Conversely, overexpression in some cancers highlights its dual context-dependent roles.
CD222 antibodies are valuable tools in research and diagnostics. They enable detection of CD222 expression in tissues or cell lines, aiding studies on receptor localization, trafficking, and IGF2-related pathways. Therapeutic applications are under exploration, particularly in oncology, where antibody-drug conjugates (ADCs) or bispecific antibodies targeting CD222 aim to deliver cytotoxic agents or enhance immune responses. Challenges remain in ensuring antibody specificity and minimizing off-target effects due to CD222's structural complexity and widespread expression. Ongoing research focuses on optimizing CD222-targeted therapies and clarifying its mechanistic roles in disease.
×
